Bio Rad Laboratories Inc (BIO.B) 2013 Q3 法說會逐字稿

Good day, ladies and gentlemen. And welcome to the Q3 2013 Bio-Rad Laboratories, Incorporated earnings conference call. My name is Glen, and I will be your operator for today.

(Operator Instructions)

As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the conference over to your host for today, Mr. Ron Hutton. Please proceed, sir.

Thank you, Glen. Before we begin the call, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations. Because our actual results may differ materially from these plans and expectations, I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our Business. The Company does not intend to update any forward-looking statements made during the call today.

With that, I'd like to turn the call over to Christine Tsingos, Senior Vice President and CFO.

Thanks, Ron. Good afternoon, everyone, and thank you for joining us. Our third quarter was a bit challenged on the top line, with net sales for the quarter of $505.1 million, an increase of 1.3% on a reported basis and versus the same-period last-year sales of $498.7 million. On a currency-neutral basis, sales increased 1.8% compared to last year. During the quarter, we experienced good currency-neutral sales growth across many of our key diagnostic product lines, as well as selected life science product lines, including $5.5 million of sales contributed by our new antibody business. Excluding currency and the addition of AbD Serotec, organic sales increased just shy of 1% compared to last year. The overall quarterly growth was tempered by a decline in Europe, as well as continued challenges for our life science segment related to the constrained academic and government research funding environment.

The reported gross margin for the quarter was better than expected at 56.3% compared to 54.9% in the year-ago period. This improvement in gross margin is the result of favorable product mix, improved utilization, and a $2.9-million one-time benefit related to a correction in the valuation of finished-good inventory for the first half of this year. Excluding this adjustment, the third-quarter gross margin was 55.7%. When compared to the same quarter of last year, remember that the third-quarter gross margin in 2012 was negatively impacted by a $3.8-million non-cash charge for a long-term environmental remediation program. Excluding this environmental remediation charge, consolidated gross margin for the third quarter of 2012 was 55.6%.

And finally, the total non-cash purchase accounting expense recorded in cost of goods sold related to prior acquisitions was $8.2 million for the quarter, which compares to $6.5 million in the year-ago period. SG&A expenses for the third quarter were $202.2 million or 40% of sales, compared to $160.1 million and 32.1% of sales last year. Increased spending versus last year is related to incremental costs associated with the recently acquired antibody business, as well as increased ERP-related expenses and amortization.

Most notably, the current-quarter SG&A also includes a $16-million accrual of the $20-million aggregate amount mentioned in our press release in connection with our efforts to resolve the previously disclosed investigation relating to the Foreign Corrupt Practices Act. When looking at SG&A spend year over year, I would also remind you that in the third quarter of last year we recorded $8.5 million of favorable impact due to the reduction in the valuation of the purchase consideration for QuantaLife. Also recorded in SG&A this quarter is $2.2 million for amortization of intangibles related to prior acquisitions.

Research and development expense in Q3 was 10.5% of sales, or $52.9 million, compared to $51.7 million in the second quarter of this year, and $47.8 million last year. This increase is primarily related to our investment in new technology and platforms for the diagnostic market, including diabetes monitoring and blood typing.

Also impacting the R&D number is a change in accounting treatment for certain French-based tax credits which had previously been accounted for as part of the tax provision, that are now being accounted for as a reduction of R&D expense. For the third quarter of 2013, this benefit was approximately $700,000, or $3.7 million year to date. Going forward, we expect R&D expense to continue to be 9% to 10% of sales.

Excluding the one-time benefit associated with the $2.9-million inventory valuation and cost of goods sold, and the $16 million of accrued legal-related expense in SG&A, the operating margin would have been approximately 8.4% for the third quarter, and in line with our previously stated outlook of 8% to 10%.

During the quarter, interest and other income was a net expense of $34.3 million. This compares to $10.8 million of net expense in the year-ago period, and $3.9 million in the second quarter. This significant increase in expense is primarily related to costs of $15.6 million associated with the redemption of our 8% subordinated notes, higher foreign exchange transactions, and $4 million of accrued interest expense related to our efforts to resolve the FCPA investigation.

The effective tax rate used for the third quarter is not meaningful, as the pre-tax income is negative. This effective rate calculation also reflects the adjustment for the refundable tax credit, and approximately $3.7 million of one-time discrete tax charges for reserves and audit settlements during the quarter. Excluding any future discrete items, we anticipate the quarterly effective tax rate to be in the range of 30% to 33%. This revised higher level is primarily the result of the change in accounting treatment for the French tax credits I spoke of earlier.

The slower-than-expected sales, combined with the FCPA-related aggregate expense accrual and the one-time costs for the bond redemption, resulted in a net loss for the third quarter of $7.1 million, and diluted earnings per share of minus $0.25.

And now, if we look at some of our segment information, life science reported sales for the third quarter declined year over year to $162.9 million, a decrease of 2.5% on a reported basis. On a currency-neutral basis, sales declined just over 1% versus last year. Sales of our life science products continue to be hampered by constraints in the global academic and government spending environment, partially offset by good demand for our new self-sorting and chromatography instruments, and the acquired antibody business.

Despite the success of our new products, organic currency-neutral growth for life science declined 4.4% for the quarter, reflecting flat to down sales in nearly all regions. It is also worth mentioning that our recent life science sales performance has been tempered by changes we are currently making in our distribution network in China, which should better position us for growth in the future.

Our clinical diagnostic group posted sales of $338.8 million, an increase of 3.2% compared to last year, both on a reported and currency-neutral basis. This growth was primarily fueled by good demand for our quality control, diabetes monitoring, and autoimmune products. On a geographic view, diagnostic currency-neutral sales for the quarter increased most notably in the US, China and Latin America. The growth was tempered somewhat by the challenging economic environment in Europe, where sales declined versus last year.

As of September 30, total cash and short-term investments were $562 million, which compares to $834 million at the end of the second quarter. The decline in cash is a result of our redeeming the high interest rate 2016 bond for a cash outlay of $312 million. Redemption of these bonds will save the Company $24 million per year of interest payments.

Cash from operations during the quarter was $62.8 million. The decrease in operating cash flow versus last year is the result of increased payments to employees and professional services, as well as the $12 million of premium paid to call the bond. EBITDA remained strong at $64 million for the quarter, and nearly $230 million year to date.

Net capital expenditures for the quarter were $24.6 million. Given the year-to-date run rate, our full-year expectation for CapEx is now slightly lower, in the $110 million to $120 million range. And finally, depreciation and amortization for the quarter was $37 million.

Moving to our outlook for the remainder of the year, on our last earnings call we guided currency-neutral revenue growth to be in the 3% to 3.5% range for the base business, and 3.5% to 4% including Serotec. We also told you that any further deterioration in Europe, or funding in the academic and government research markets, could make our goals difficult to achieve. Given our year-to-date currency-neutral growth of about 2% for the base business, and 3.1% including Serotec, and combined with the continued European challenges and constrained funding environment, we now believe the full-year currency-neutral sales growth for 2013 will likely remain in that same 2% to 3% range we have experienced so far this year.

As is typical with our historical patterns, the fourth quarter often reflects a sequentially lower gross margin, as the product mix shifts toward a higher percentage of instrument sales, as well as a lower operating margin reflecting higher SG&A expenses, which are typical of our year end. With that in mind, and given the year-to-date results, we believe that our operating margin will be between 8% and 9% for the full year, excluding the accrual for our FCPA-related matter. As has been our practice in prior years, we will share our thinking and outlook for 2014 in February during the fourth-quarter earnings call.

And now we are happy to take your questions.

(Operator Instructions)

Brandon Couillard, Jefferies.

Christine, could you help us quantify the aggregate dollar amount booked in the P&L for the ERP system in the third quarter? And perhaps if you could break out the capitalized about.

I don't have the exact numbers with me, Brandon. I can tell you that, if where your question is headed is around how much of the project was expensed during the quarter that was originally intended to be capitalized, it's about $3 million of higher expense than we would have originally anticipated.

Cash is the same, out the door. And so, let me see if I can track this down while we are doing other questions in terms of the exact dollars of capital and expenses in the third quarter.

Okay. And I don't know if Brad or John are there, but with respect to the Life Science business in the third quarter, could you elaborate on what you saw either from a product perspective, any color you could give us by geography, and how you would characterize the competitive landscape? And then perhaps a view on the change in the distribution network in China, some detail there would be helpful.

That's a lot of questions there. In general, we didn't see a lot in significant changes in competitiveness of the products. In fact, we have a pretty strong order pipeline. We did have some timing issues as we switched over from the QX100 to QX200. Some of those sales which we could've enjoyed in the third quarter will slip into the fourth quarter.

In general, Europe is stabilizing for us. I think were pretty happy about that. The US continues to suffer from sequestration. We didn't see any impact of the government shutdown in the third quarter, because that obviously happened after. But we really did see some changes in China, some shortfalls in China.

And, really, what we're doing is we are moving to a much more closer model to our customers, from large distributors to a more closer, smaller distributor model. And that certainly has had an impact. But that is all consistent with us putting in a better position in the future.

On the Diagnostics side, our sales growth is primarily coming from US and China in the area of diabetes controls and autoimmune testing. Where we were challenged, we continue to be challenged, is in Europe. And we've had some declines there.

Thanks. And, John, could you give us an update on where you stand with respect to launching the new blood typing system in the US market? Have you submitted that to the FDA? And what is the timeline, the outlook for commercialization here?

Yes, we are still completing our clinical trials at this time. And we hope to submit to FDA soon. And then after that, it's a little bit about anybody's guess about how long that is going to take.

All right, thank you.

Justin Bowers, Leerink Swann.

Just continuing with China there, is there any way you can maybe directionally talk about -- was it down or flat, up slightly in the quarter? And then in terms of the changes you are making there, maybe timing around when you expect to see an inflection point? And then maybe how you expect that to help the biz going forward.

Certainly it was down for the quarter. We expect over the next few quarters for it to rebound. And really the most important thing for us is to be closer to our customers. And we find that that is a lot easier to do with smaller, more focused distributors versus larger distributors. And that was certainly the move we made.

It is all consistent with us. As we move to a more content solution-based approach, what we need is a much closer relationship with our customers. And so that is why we've made these moves.

Okay. And just as a follow-up to that, what proportion of the Life Science business is exposed to China currently?

We don't break out to that level of detail.

Okay. And then just maybe from a high level, what are you guys seeing in the DPCR market? And maybe talk about the trajectory there and what some of the changes in the competitive dynamics over the last few months.

Actually, things are going quite well. We did launch the QX200. As you are aware, there were a couple of new competitors that came on the market early in the year and that slowed things additionally as people stopped to look at that, those products.

But the trajectory of our business going forward is accelerating. We do have, again, good visibility into the fourth quarter and we are doing quite well. This is a market that is now hitting its stride. I think people are -- the applications that are being published, the number of papers, have really expanded the use, as we predicted, far beyond our own imagination into some really exciting areas. So, we are real excited about the opportunity in the future.

Okay, great. And then just two more quick ones. With SG&A that came in a little better than us. And was just curious if that is due to any change that you guys are operating the business, or if it is accounting related for the ERP system. And then, finally, you said something about the inventory charge in your prepared remarks. And I was just wondering if you could repeat that and the impact on gross margins.

Sure. I'm not sure, when you talk about SG&A was better than you were expecting, I don't know what your expectations were. But we think SG&A came in obviously much higher than we had originally anticipated, primarily driven by the $16 million accrual. But then also some increased ERP-related spend during the quarter.

Okay, that's helpful. I was looking at it adjusting for the charge there. But that's helpful, thanks. Thank you.

I don't disagree with you because, given the lack of air cover on the top line, the margin hung in there. As far as your question on clarification of what is going on in cost of goods sold and the gross margin, during the quarter we recorded a $2.9 million one-time benefit. And this is basically to make a correction in the valuation of our finished goods inventory for the first half of the year. So, through the nine-month period.

And that, of course, is a reduction of cost of goods and an improvement of the margin. If we were to take that out, the base gross margin was 55.7%, and that compares to a base gross margin in the third quarter of 2012 of 55.6%. I'm not sure, Justin, if that clarifies your question or if you needed something different.

Yes, it does. I did not get the adjusted gross margin figure there and I was just trying to reconcile it. But I got it now. Thanks so much. I am all set.

Jeffrey Matthews, Ram Partners.

On the challenges in Europe, I'm particularly interested in whether you think you are losing share in France in Diagnostics, or whether you think this is just a market-related slowdown?

In Europe, our primary declines there are coming in the infectious disease blood virus testing area. I would say that is masking largely where we are actually getting some growth. It is a big chunk of business for us there. And any slowness or declines there do affect the overall results.

Okay. Is it a market issue or is it more of you are losing tenders?

Most of this business is tender. And so, as those tenders go, you either win big or you lose big. So, it's an interesting dynamic that is happening there now, as customers are extending their tenders beyond a usual two-, three-, four-year tender. We are seeing tenders much longer than that now. So that is driving a lot of heavy competition for tenders. And we are just not that interested in pursuing some of these at such low prices.

Okay. And then I think in the last call you talked about downsizing a bit on the cost side in Europe. Has that happened?

I think a lot of it has been in process. You're talking about when we talked about it in the first quarter of accruing for some changes in Europe, and that is ongoing, and it is something we continue to look at.

Okay. Europe is notoriously difficult to reduce headcount. Is there any structural impediment to it? Or has that been proceeding as you had planned?

No, I don't think there are any structural impediments. It is just a question of the process. It is of a long drawn-out process.

Sure. Okay. And then I wanted to just understand the comments on the China distribution a little better. Is the shift a result of changes in the China marketplace itself? Or did you go into China with the wrong distributors, I guess is a bad way of asking it.

No. I think this is really adjustments that we've wanted to make. As Brad said, it is just shifting our distribution strategy a little bit, and adjusting for that.

Okay. ERP -- have you rolled it out or gone live in any other spots?

No, not yet. We had pretty good luck with our first deployment. We are obviously doing a little clean up from that and getting ready for the second deployment. Probably the next deployment will be some time late next year, something like that.

In the first half of 2015. And that will be the rest of the US.

Okay. Because in my notes I had you saying on the last call that you were looking to work on the rest of the US towards the fall. But did I get that wrong?

No. It is true that we are in the midst now of starting to plan for the second deployment, which is the rest of the US. So that is in the fall commentary from before. And, as we start 2014, we will go in depth in terms of that blueprinting process and begin the implementation throughout the year. And then hopefully go live very early of 2015.

Okay. And no horror stories, no freak outs so far?

Not yet.

No, we are still in business and serving our customers. Obviously, there are always challenges of getting people to adopt to a new system. But I don't think there is anything different here than other companies would face. And I think we've been pleased with the results so far.

Good, okay. Thanks very much.

(Operator Instructions)

Sam Siegel, Senator.

I just wanted to clarify a little bit an earlier question that was asked around timing. Obviously, it seems that some of the underlying markets were softer than hoped. But the tone seems a little bit more constructive than perhaps the softness in the quarter might suggest. So, whether it's switching distributors in China or otherwise, just bigger picture how are you guys feeling as you round out the year -- more or less the same trajectory of growth, incrementally worse, or encouraged by certain markets? Maybe just big picture, if you could try to characterize the mindset as we finish out this year and head into next.

I think we are thinking more of the same, a similar pattern for the rest of the year as we have seen for the first three quarters. I don't see any major changes up or down. That's about where we are.

I think the only thing I would add, Sam, as you know our fourth quarter is generally our largest quarter of the year. And I think that the pipeline is indicating the same pattern to happen this year, as well. In terms of overall growth, as Norman was talking about, we had a decent fourth quarter in the year-ago period, so the growth rates may still be in that 2% for the base business, 3% with the acquired sales range, when all is said and done. But, the pipeline is indicating that Q4 should have a similar pattern to what we've seen in prior years.

Okay, that was my sense of it. That is helpful. I appreciate clarifying that.

Jeffrey Matthews, Ram Partners.

Two questions. And one is always asked. I'd like to ask Norman about the acquisition environment. But first I wanted to follow up again on something that came up on the last-quarter call, where I think Japan was a little off. And the comment last time was you saw a shift in how they were funding research, you expected it to come back in the second half. And I'm wondering if that was the case.

That was more of a Life Science?

Yes.

I don't think there's been any change in Japan that I'm aware of.

Japan is slow and we don't expect to see really any -- obviously, the currency is way off, but we don't expect any really turnaround in Japan until the first quarter of 2014. A lot of business has been pushed off. It continues to be slow and down for the quarter, and I think we are seeing that trend is going to continue.

For the Life Science market.

And that stems from just government policy, Brad?

Yes, government policy. What they did is they are struggling how they are going to fund research. And what they did is they allowed the researchers to put off their spend, so we don't really have that cliff that we usually see in the fourth quarter, our fourth quarter. It is all being pushed into the first quarter, our first quarter, which would be their fourth quarter of their fiscal year.

Got it. And could I just follow-up before asking Norm about acquisitions. What have you seen in China? There is a huge variety of opinions out there on what companies are seeing out of China these days. And distribution issues aside, do you see any change in appetite?

I think the idea of China being a runaway growth engine is probably not the case going forward. I think there is a lot more critical thinking in how grants and government funding is doled out. Certainly, you have the local pharma market that is coming up, and the CRO business is coming up, as well. So, in general, I think China is still a nice upside. But I would say I'm of the school that the growth is going to be probably more tempered at a market growth around 10% to 12% versus may be 14% to 17%.

Okay, thank you. And then acquisitions?

We continue to look at acquisitions. We've got a couple of interesting things we are looking at at the moment. And, as you know, you can never tell whether these things are going to come to fruition or not. I think that certainly the ones that we have done earlier, especially the Life Science acquisitions, that I think they are proving to be pretty good additions for us. And we are rolling out those products. So we feel pretty good about what we've done. Again, we've got a few more things in the pipeline.

Got it. Okay, thanks.

Brian Turner, Levin Capital.

Two questions. First question, can you help me understand, if you had to put a weighting on the softness in Europe versus the academic softness, is it equally in terms of the contribution to your 2%, 3% top-line guidance? And then if you had to take a guess, which one do you think would turn more quickly? That's the first question.

The second question is related to Sartorius. Have you increased your number of shares held since last quarter? Thanks.

The first question, I think it is hard to quantify off the top of my head which has more impact. I think that in terms of which part of the business would expect to turn faster, probably the Life Science part. The Diagnostics part tends to be a more steady-state business. But, again, it is very hard to quantify for you which one has more impact. They both have some impact. We do continue to have an interest in Sartorius, and do from time to time accumulate shares.

Any other questions, Brian?

No, that's it. Thank you.

And at this time we have no further questions from the phone lines.

Okay, great. Thank you, everyone, for taking the time to join us today. Goodbye.

Ladies and gentlemen, that concludes today's conference. Thank you for your participation. You may now disconnect and have a great evening.